Biotechnology company Cereno Scientific (Nasdaq First North:CRNO B) announced on Friday that the first patient has been dosed with CS1 under its Expanded Access Program (EAP) for Pulmonary Arterial Hypertension (PAH).
This program allows patients who completed the Phase II trial to continue receiving CS1 based on perceived benefit, as determined by both the patient and physician.
The EAP aims to gather extensive data on long-term CS1 usage, supporting future regulatory discussions and pivotal trial planning. Approved since January 30, 2024, the EAP is an extension of the Phase II trial under an FDA protocol.
CS1, an HDAC inhibitor targeting PAH, has shown potential in Phase II trials, with topline results expected in Q3 2024.
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Agios receives orphan drug designation for tebapivat in MDS
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Sun Pharma and Moebius Medical's MM-II receives Fast Track designation for osteoarthritis knee pain
Vivet Therapeutics receives Orphan Drug Designation from European Commission for VTX-806